Evidence map›Paper›PMID 40027184›Full record

ArticleInternational journal of medical sciences2025

A synthetic molecule targeting STAT3 against human oral squamous cell carcinoma cells.

Li-Yuan Bai, Eman M E Dokla, Po-Chen Chu, Chia-Hsien Feng, Jing-Lan Hu, Liang-Jun Wang, Jing-Ru Weng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li-Yuan BaiDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Eman M E DoklaPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo 115, Egypt.
Po-Chen ChuDepartment of Cosmeceutics and Graduate Institute of Cosmeceutics, China Medical University, Taichung 404, Taiwan.
Chia-Hsien FengDepartment of Fragrance and Cosmetic Science, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Jing-Lan HuDivision of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Liang-Jun WangDepartment of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan.
Jing-Ru WengDepartment of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC), one of the most common cancers in Taiwan, needs new therapeutic agents and treatments. The aim of this study was to investigate the anti-proliferative activity of {

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellMouth NeoplasmsOxadiazolesPyridinesSTAT3 Transcription FactorApoptosisbeta CateninCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemAntineoplastic Agentsbeta CateninOxadiazolesPyridinesSTAT3 protein, humanSTAT3 Transcription FactorapoptosisMAPKmigrationOral squamous cell carcinomaSTAT3

Identifiers

PMID40027184
PMCPMC11866527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.